当前位置:首页 - 行情中心 - 海昇药业(920656) - 财务分析 - 现金流量表

海昇药业

(920656)

  

流通市值:5.29亿  总市值:16.33亿
流通股本:3237.63万   总股本:1.00亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金34,916,362138,931,947.9391,582,662.6847,696,273.22
  收到其他与经营活动有关的现金545,873.828,317,631.848,052,732.73982,729.48
  经营活动现金流入小计35,462,235.82147,249,579.7799,635,395.4148,679,002.7
  购买商品、接受劳务支付的现金12,351,791.954,493,312.9737,543,157.6223,942,331.97
  支付给职工以及为职工支付的现金8,807,118.2237,683,370.8523,984,085.9615,865,989.37
  支付的各项税费8,417,874.213,199,861.1713,715,871.368,636,191.51
  支付其他与经营活动有关的现金1,400,348.886,544,331.885,462,383.63,715,583.42
  经营活动现金流出小计30,977,133.2111,920,876.8780,705,498.5452,160,096.27
  经营活动产生的现金流量净额4,485,102.6235,328,702.918,929,896.87-3,481,093.57
二、投资活动产生的现金流量:
  取得投资收益收到的现金2,062,125.756,984,077.423,111,195.972,713,798.71
  收到的其他与投资活动有关的现金1,000,000,0002,515,000,0001,831,000,0001,636,000,000
  投资活动现金流入小计1,002,062,125.752,521,984,077.421,834,111,195.971,638,713,798.71
  购建固定资产、无形资产和其他长期资产支付的现金5,372,837.3712,952,404.711,265,115.097,164,144.72
  支付其他与投资活动有关的现金945,000,0002,570,000,0002,191,000,0001,791,000,000
  投资活动现金流出小计950,372,837.372,582,952,404.72,202,265,115.091,798,164,144.72
  投资活动产生的现金流量净额51,689,288.38-60,968,327.28-368,153,919.12-159,450,346.01
三、筹资活动产生的现金流量:
  分配股利、利润或偿付利息支付的现金-20,000,00020,000,00020,000,000
  支付其他与筹资活动有关的现金-19,698,10019,698,1009,798,100
  筹资活动现金流出平衡项目-000
  筹资活动现金流出小计-39,698,10039,698,10029,798,100
  筹资活动产生的现金流量净额平衡项目-000
  筹资活动产生的现金流量净额--39,698,100-39,698,100-29,798,100
四、汇率变动对现金及现金等价物的影响-732,110.49-696,089.16-36,256.69104,897.98
五、现金及现金等价物净增加额55,442,280.51-66,033,813.54-388,958,378.94-192,624,641.6
  加:期初现金及现金等价物余额380,610,266.95446,644,080.49446,644,080.49446,644,080.49
  期末现金及现金等价物余额436,052,547.46380,610,266.9557,685,701.55254,019,438.89
补充资料:
  净利润-69,456,983.52-30,325,906.98
  资产减值准备-472,839.65-5,028.7
  固定资产和投资性房地产折旧-17,164,612.59-8,330,573.95
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-17,164,612.59-8,330,573.95
  无形资产摊销-510,435.5-414,674.46
  长期待摊费用摊销-176,450.04-88,225.02
  公允价值变动损失--216,333--
  财务费用-696,089.16--43,864.99
  投资损失--6,984,077.42--2,713,798.71
  递延所得税--877,694.43--132,367.94
  其中:递延所得税资产减少--877,694.43--132,367.94
  存货的减少--9,946,728.03--4,837,487.71
  经营性应收项目的减少--47,773,503.47--13,277,196.6
  经营性应付项目的增加-10,840,283.23--23,624,858.46
  其他-1,347,193.45-1,106,647.52
  现金的期末余额-380,610,266.95-254,019,438.89
  减:现金的期初余额-446,644,080.49-446,644,080.49
  现金及现金等价物的净增加额--66,033,813.54--192,624,641.6
公告日期2026-04-162026-04-162025-10-272025-08-21
审计意见(境内)标准无保留意见
TOP↑